Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Brian G. Weinshenker, Benjamin Greenberg et al.|The Lancet Neurology|2020Cited by 495
NKT Cell-Dependent Amelioration of a Mouse Model of Multiple Sclerosis by Altering Gut FloraHiroaki Yokote, Takashi Yamamura|American Journal Of Pathology|2008Cited by 268
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiologyKazuo Fujihara, Takashi Yamamura, Masayuki Haramura et al.|Neurology Neuroimmunology & Neuroinflammation|2020Cited by 248
Neuropeptide Y (NPY) Suppresses Experimental Autoimmune Encephalomyelitis: NPY1 Receptor-Specific Inhibition of Autoreactive Th1 Responses In VivoSammy Bedoui, Takashi Yamamura, Youwei Lin et al.|The Journal of Immunology|2003Cited by 100
Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis OpticaNorio Chihara, Takashi Yamamura, Toshimasa Aranami et al.|PLoS ONE|2013Cited by 93